Core Insights - Editas Medicine reported a wider loss of 55 cents per share in Q4 2024, compared to the Zacks Consensus Estimate of a loss of 39 cents, and a loss of 23 cents per share in the same quarter last year [1][9] - The company's total revenues for Q4 2024 were $30.6 million, down 49% from $60 million in Q4 2023, missing the Zacks Consensus Estimate of $38 million [2][9] - Editas' stock is declining in pre-market trading due to weaker-than-expected earnings results [3] Financial Performance - R&D expenses decreased by 30% to $48.6 million in Q4 2024 from $69.6 million in Q4 2023, attributed to prior sublicense payments to Vertex Pharmaceuticals [4] - General and administrative expenses rose by 13% year-over-year to $16.4 million due to increased professional service costs [4] - Restructuring charges amounted to $12.2 million in the quarter due to the discontinuation of the reni-cel program and workforce reduction, with no such charges recorded in the previous year [5] Cash Position - As of December 31, 2024, Editas had cash, cash equivalents, and investments totaling $269.9 million, up from $265.1 million as of September 30, 2024 [6] - The company expects its cash reserves to fund operations and capital expenditures into Q2 2027, with estimated total expenses of approximately $45-$55 million covering the termination of the reni-cel program [6] Market Performance - Editas shares have declined by 8.1% over the past three months, compared to a 2.3% decline in the industry [7] Strategic Updates - Editas has no approved products and is focusing on pipeline development, having ended the reni-cel program in December 2024 due to the lack of a commercial partner [10] - The company is prioritizing in vivo pipeline development, with plans to announce an in vivo hematopoietic stem cell development candidate by mid-2025 [12][13] - Editas has demonstrated effective gene editing in hematopoietic stem cells and liver cells, with further data expected by the end of 2025 [13][14] Licensing and Collaborations - In late 2023, Vertex Pharmaceuticals in-licensed rights to Editas' Cas9 gene editing tool for its sickle cell disease gene therapy [8] - Editas received $57 million in upfront cash from the sale of future license fees related to its Cas9 license agreement with Vertex [8]

Core Insights - Editas Medicine reported a quarterly loss of $0.55 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.39, and compared to a loss of $0.23 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $30.6 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 19.18% and down from $60.05 million year-over-year, reflecting ongoing challenges in meeting revenue expectations [2] - Editas shares have increased by approximately 38.6% since the beginning of the year, contrasting with a decline of 1.8% in the S&P 500, suggesting a relative outperformance in the market [3] Earnings Outlook - The earnings outlook for Editas is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.59 on revenues of $1.07 million, and for the current fiscal year at -$1.66 on revenues of $9.32 million, indicating continued expected losses [7] - The company currently holds a Zacks Rank 3 (Hold), suggesting that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Editas belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable industry outlook that could positively influence stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could be a useful metric for investors [5]

Editas Medicine, Inc. (NASDAQ:EDIT) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET Company Participants Erick Lucera - Chief Financial Officer Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha All right. Thanks, everyone, for joining us for the next half hour. My name is Dae Gon Ha, one of the biotech analysts at Stifel. So with me for the next half hour, we've got Editas Medicine. So from Editas, we have Erick Lucera, Chief Financial Officer and Christine [indiscernible] VP of IR. ...

Summary of Editas Medicine, Inc. Conference Call Company Overview - **Company**: Editas Medicine, Inc. (NASDAQ:EDIT) - **Event**: 2024 Cantor Global Healthcare Conference - **Date**: September 17, 2024 - **Participants**: Gilmore O'Neill (CEO), Eric Schmidt (Cantor Fitzgerald Analyst) Core Company Strategies - **Three Pillars of Strategy**: 1. Drive Renicel to approval 2. Build a differentiated in-vivo discovery pipeline focusing on first-in-class or best-in-class therapeutics 3. Utilize non-dilutive financing methods, including out-licensing foundational intellectual property from Broad, Harvard, and MIT [2][12][16] Gene Editing Technology - **Differentiation**: Editas utilizes the AsCas12a enzyme, which is characterized by high efficiency and fidelity, making off-target editing difficult to detect compared to Cas12 [5][6] - **Clinical Validation**: AsCas12a has been validated in clinical settings, particularly in the Reni-cel therapy [5] Immediate Priorities - Focus on developing in-vivo medicines that are first-in-class and best-in-class, with a unique approach of functional upregulation rather than gene knockdown [8][9] - Target specific tissues, particularly hematopoietic stem cells for treating sickle cell disease and beta thalassemia [10][41] Reni-cel Program Insights - **Efficacy**: Reni-cel has shown significant efficacy, with patients experiencing a reduction in vaso-occlusive events (VOEs) from a mean of 4 to zero post-transplant [13][14] - **Market Strategy**: There is an interest in potentially partnering Reni-cel to expand market reach outside the U.S. [16] - **Market Dynamics**: The company believes the cell therapy market is at the beginning of a growth curve, with increasing demand and understanding among patients and physicians [18][19] Challenges and Opportunities - **Patient Education**: There is a need for increased education regarding gene therapies among patients and referring physicians to drive demand [19][24] - **Contracting and Reimbursement**: The contracting process with treatment centers is expected to mature, which will facilitate market entry [20][21] - **Payer Engagement**: The evolution of payer policies is crucial for therapy adoption, with ongoing efforts to engage with Medicaid and commercial payers [22][25] Competitive Landscape - Editas positions itself as a "fast follower" in the gene therapy space, learning from the experiences of earlier entrants like Vertex and bluebird bio [26][30] - The company aims to leverage its differentiated technology and operational efficiencies to capture market share despite being later to market [35] Future Directions - **In-vivo Programs**: Editas is focusing on in-vivo hematopoietic stem cell therapies, with several programs identified that align with their strategic goals [51] - **Biomarker Utilization**: The company plans to select targets based on genetic variants and quick biomarker readouts to ensure effective clinical outcomes [49] Conclusion - Editas Medicine is strategically positioned to leverage its innovative gene editing technology and therapeutic focus to address significant unmet medical needs in genetic disorders, particularly sickle cell disease and beta thalassemia, while navigating the complexities of market entry and patient education [2][8][19]

Editas Medicine, Inc. (EDIT) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a loss of 56 cents per share in the year-ago quarter. Collaboration and other research and development (R&D) revenues, which comprise the company's top line, were $0.5 million in the second quarter, down from $2.9 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $7 million. ...

Editas Medicine (EDIT) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.56 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -18.84%. A quarter ago, it was expected that this genome editing company would post a loss of $0.63 per share when it actually produced a loss of $0.76, delivering a surprise of -20.63%. Over the last four quarters, the co ...

Core Insights - Editas Medicine is making significant progress in its clinical trials, particularly with its product reni-cel for sickle cell disease, and is on track to present additional clinical data from the RUBY and EdiTHAL trials by year-end 2024 [1][3][4] - The company maintains a strong financial position with cash reserves expected to fund operations into 2026 [6][13] - The net loss for the second quarter of 2024 was $67.6 million, an increase from $40.3 million in the same period in 2023, indicating rising operational costs [7][12] Clinical Development - Reni-cel is positioned as a best-in-class treatment for sickle cell disease, with substantial clinical updates shared mid-year and ongoing patient enrollment in the RUBY trial [2][3] - The adolescent cohort of the RUBY trial has completed enrollment, and the company continues to dose adult patients [3] - The EdiTHAL trial for transfusion-dependent beta thalassemia has also completed enrollment for the adult cohort, with ongoing patient dosing [4] Financial Performance - As of June 30, 2024, the company reported cash, cash equivalents, and marketable securities totaling $318.3 million, down from $376.8 million as of March 31, 2024 [6][13] - Collaboration and other research and development revenues decreased to $0.5 million in Q2 2024 from $2.9 million in Q2 2023, primarily due to reduced drug supply activity [7][12] - Research and development expenses increased significantly to $54.2 million in Q2 2024, up from $29.8 million in Q2 2023, driven by costs associated with the accelerated progression of the reni-cel program [7][8][12] Strategic Outlook - The company is on track to establish in vivo preclinical proof-of-concept for an undisclosed indication by year-end 2024, indicating ongoing innovation in its research strategy [5] - Editas Medicine aims to develop transformative genomic medicines for serious diseases, leveraging its expertise in CRISPR technology [10]

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream. Clinical data from pati ...

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins.Participants should a ...

Editas Medicine, Inc. (EDIT) incurred a loss of 23 cents per share in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 52 cents. The company had reported a loss of 88 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $60 million in the reported quarter, up significantly from $6.5 million reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate o ...